Open Access Government
April 8, 2025
Peter Verheyen
Quantum bits and consciousness: Biochemical information processing Dr Peter Verheyen, DMD from the Sola Society & Academy, at Vienna University, explores quantum bits and consciousness, focusing this time on biochemical information processing. Consciousness is an extremely difficult concept. A widespread theorem in neuroscience states that consciousness arises from biological information...
Open Access Government
April 9, 2024
Erika Dyck
Who will staff the psychedelic resurgence? Erika Dyck, Professor and Canada Research Chair in History of Health & Social Justice from the University of Saskatchewan, provides an intriguing answer to this question. On 6th February 2024, a research team at Le Grau-du-Roi Hospital in the south of France, led by addictologist Amandine Luquiens, put their first subject through a clinical trial with...
Open Access Government
January 22, 2024
Erika Dyck
Will psychedelic research and the ‘psychedelic renaissance’ create another generational divide? Erika Dyck, Canada Research Chair in History of Health & Social Justice at the University of Saskatchewan, discusses changing attitudes to psychedelics and the challenges in forming a strong evidence base from available psychedelic research. As psychedelics re-emerge in the 21st century, their...
Open Access Government
October 25, 2023
Erika Dyck
Professor Erika Dyck, Canada Research Chair in the History of Health & Social Justice, discusses the extensive history and growing medical application of psychedelics known as the psychedelic renaissance. British psychiatrist Ben Sessa re-introduced the concept of the psychedelic renaissance in 2011, suggesting that it was perhaps time to rethink the role of psychedelic drugs in medicine. The...
Open Access Government
July 13, 2023
Cosmo Feilding-Mellen
Using psychedelics to mitigate Treatment Resistant Depression Cosmo Feilding-Mellen, CEO, Beckley Psytech, charts the role of psychedelics in mitigating Treatment Resistant Depression. When it comes to treating neuropsychiatric and mental health conditions, we have to accept that one size does not fit all. For some, talking therapies like cognitive behavioural therapy plus antidepressants like...
Open Access Government
July 10, 2023
Erika Dyck
1 citation
The history of psychedelics and why psychedelic stories matter Erika Dyck argues that how people learn about psychedelics today matters, based on the histories of these drugs and how they have been and should be used in clinical medicine. While these substances have piqued the interest and influenced the attitudes of individuals across academia, culture, and medicine, expanding before and well...
Open Access Government
July 10, 2023
Jim Gilligan
Leveraging psychedelic therapies for binge eating disorder Here Tryp Therapeutics examine the viability of using psychedelic therapies for Binge Eating Disorder and the potential results that using psychedelic-assisted psychotherapy could have on different eating disorders. Tryp Therapeutics is a clinical-stage biotechnology company dedicated to the development of exclusive and innovative...
Open Access Government
July 10, 2023
Tadeusz Hawrot
Tadeusz Hawrot, Founder and Executive Director of PAREA, states the case for a new focus in the EU’s mental health care approach, that is the underserved area of psychedelic therapies. As we navigate deeper into the 21st century, the importance of mental health care is gaining increasing recognition. But we still have a long way to go. The OECD estimates that mental illness affects one in two...
Open Access Government
April 12, 2023
Erika Dyck
Psychedelic therapies are returning to psychiatry Professor Erika Dyck, Canada Research Chair in History of Health & Social Justice at the University of Saskatchewan argues that psychedelic drugs and therapies, whether conducted in ceremonial settings or clinical ones, are being touted as life-changing moments for their capacity to efficiently transform an individual's perspective on...
Open Access Government
April 12, 2023
Jessica R. Riggleman
Jessica Riggleman, Owner of Raeco, LLC, examines the global regulatory landscape for psychedelic drugs, with a particular focus on Schedule I classification. Depending on the country and specific drug, the global regulatory landscape for psychedelic drugs is complex and variable. Generally, most countries regulate psychedelic drugs as controlled substances, with varying degrees of legal and...
Open Access Government
January 6, 2023
Tadeusz Hawrot, David R. Badcock
Brain health conditions: Excellence in psychedelic treatments Psychedelic treatments open up an unparalleled window of opportunity, but we need to get ready for their roll-out. Mental healthcare is in crisis, and we don't have the tools to truly help millions of Europeans in need. In the EU, a shocking number of over 100 million people are affected by mental health conditions and alcohol use...